Thiazolidinediones and cardiovascular outcomes in type 2 diabetes Reply

被引：0
|
作者：
Singh, S. [1 ]
Furberg, C. D. [1 ]
机构：
[1] Wake Forest Univ, Winston Salem, NC 27109 USA
来源：
HEART | 2009年 / 95卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [31] Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes REPLY
    不详
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (03): : 300 - 301
  • [32] Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Chiu, Lu-Ting
    Hsu, Chih-Cheng
    Hou, Ming-Chih
    Hwu, Chii-Min
    LIVER INTERNATIONAL, 2021, 41 (01) : 110 - 122
  • [33] Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    Green, Jennifer B.
    Bethel, M. Angelyn
    Armstrong, Paul W.
    Buse, John B.
    Engel, Samuel S.
    Garg, Jyotsna
    Josse, Robert
    Kaufman, Keith D.
    Koglin, Joerg
    Korn, Scott
    Lachin, John M.
    McGuire, Darren K.
    Pencina, Michael J.
    Standl, Eberhard
    Stein, Peter P.
    Suryawanshi, Shailaja
    Van de Werf, Frans
    Peterson, Eric D.
    Holman, Rury R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03): : 232 - 242
  • [34] Attenuating cardiovascular disease risk factors in patients with type 2 diabetes with metformin, sulfonylureas, and thiazolidinediones
    Buse, J
    Harmel, AP
    Kendall, D
    Boyle, P
    Marchetti, A
    Lau, H
    DIABETES, 2003, 52 : A443 - A443
  • [35] SAXAGLIPTIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES
    Raz, I
    Scirica, B. M.
    Braunwald, E.
    Mosenzon, O.
    Hirshberg, B.
    Wiviott, S. D.
    Frederich, R.
    Davidson, J.
    Leiter, L. A.
    Bhatt, D. L.
    HYPERTENSION, 2014, 63 (06) : E167 - E167
  • [36] Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
    Ganda, Om P.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2016, 83 : S11 - S17
  • [37] Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
    Gerstein, Hertzel C.
    Sattar, Naveed
    Rosenstock, Julio
    Ramasundarahettige, Chinthanie
    Pratley, Richard
    Lopes, Renato D.
    Lam, Carolyn S. P.
    Khurmi, Nardev S.
    Heenan, Laura
    Del Prato, Stefano
    Dyal, Leanne
    Branch, Kelley
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10): : 896 - 907
  • [38] Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome
    Drexler, Andrew J.
    Nesto, Richard W.
    Abrahamson, Martin J.
    Bakris, George
    Bell, David
    Brunzell, John
    Dandona, Paresh
    Davidson, Jaime
    Fonseca, Vivian
    Fowler, Michael
    Frye, Robert
    Giles, Thomas
    Haffner, Steven
    Hollenberg, Norman
    Hsueh, Willa
    Law, Ronald
    Plutzky, Jorge
    Ratner, Robert
    Reusch, Jane
    Selwyn, Andrew
    Sowers, James
    Wyne, Kathleen
    Young, Lawrence H.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2005, 3 (02) : 147 - 173
  • [39] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Zweck, Elric
    Westenfeld, Ralf
    Szendroedi, Julia
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2075 - 2076
  • [40] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Rosenstein, Robert
    Hough, Augustus
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1093 - 1094
12345